Changes in serum cholesterol and triglyceride levels in chronic hepatitis B patients treated with Interferon - α İnterferon - α i̇le tedavi̇ edi̇len kroni̇k hepati̇t b'li̇ olgularda serum kolesterol ve tri̇gli̇seri̇d düzeyi̇ deǧi̇şi̇kli̇kleri̇
Gulhane Medical Journal, cilt.44, sa.3, ss.306-308, 2002 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 44 Sayı: 3
- Basım Tarihi: 2002
- Dergi Adı: Gulhane Medical Journal
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.306-308
- Anahtar Kelimeler: Cholesterol, Hepatitis B, Interferon-α, Triglyceride
- Sağlık Bilimleri Üniversitesi Adresli: Hayır
Özet
Interferons decrease lipoprotein lipase, hepatic triglyceride lipase and plasma cholesteryl ester protein activity. Decrease in lipoprotein lipase activity causes decrease in very low density lipoprotein clerance. Thus changes occur in serum cholesterol and tryglyceride levels. The aim of this study was to investigate if serum cholesterol and triglyceride levels were affected in patients with chronic hepatitis B treated with interferon-α (IFN-α). Fourty patients (35 male and 5 female) with chronic hepatitis B treated with 4,5/5 MU IFN-α daily were enrolled in our study. Serum cholesterol and tryglyceride levels of the patients were assayed before the therapy, in 1st, 3rd, and 6th months of the therapy and 6 months after cessation of therapy. The baseline serum cholesterol levels (186 ± 38.34 mg/dl) of the patients transiently decreased and the average of the three levels assessed during the therapy was 147 ± 23.20 mg/dl (p < 0.001). There was no significant difference between serum cholesterol levels before the therapy and 6 months after the therapy ended (p > 0.05). The serum triglyceride levels before the therapy (120 ± 51.97 mg/dl) increased significantly with the therapy (226 ± 163.63 mg/dl, p < 0.001) and decreased to their baseline levels (110 ± 60.56 mg/dl, p < 0.001) 6 months after cessation of the therapy. In our study group, no patient suffered from severe hypertriglyceridemia. However, since severe hypertriglyceridemia was reported in previous studies with IFN-α therapy, the serum lipid profile in such patients should be monitorized to be aware of severe hypertriglyceridemia.